Innoplexus Inc, a subsidiary of Innoplexus AG, Frankfurt, which has developed the most comprehensive, industry-validated, AI-powered Drug Discovery and Development platform, announced today the appointment of Rita Kelley as Senior Vice President Corporate Development and Marketing. Rita will also act as Managing Director USA. Ms. Kelley is highly accomplished biotechnology and pharmaceutical executive with more than 20 years of leadership experience across strategy, commercial, and business development functions.

“We are extremely pleased that Rita has chosen to join Innoplexus at this exciting time in the company’s development,” said Dr. Gunjan Bhardwaj, Founder, and CEO of Innoplexus. “Rita’s extensive expertise will be crucial for Innoplexus as we plan for the commercial growth of our platform. Innoplexus has an industry-validated, AI-powered, Drug Discovery, and Development platform that’s creating value for diverse stakeholders such as Pharma, Biotechs, CROs, Research Organizations, Patients, Governments and Investors by driving innovation in science, clinical development, and commercialization.

Prior to joining Innoplexus, Ms. Kelley served as Vice President of Medical and Commercial Strategy at BioNTech SE, where she helped build and significantly grow the novel mRNA immunotherapy pipeline in cancer and rare diseases.

“I am very excited to be joining the Innoplexus team. Innoplexus has the ability to drive a paradigm shift in drug discovery and development, which in turn will bring life-transforming medicines to patients across the globe faster”, said Ms. Kelley.

Ms. Kelley has held senior executive global positions at Pfizer, Novartis, and Merck, where she led the global effort that successfully achieved the historic, first in class, best in class approval of Keytruda® for treating MSI-H cancers, regardless of biology, gaining approval in 22 indications. Ms. Kelley has also successfully launched five products globally which have achieved over USD 1B in sales. Through these efforts, she has excelled in bringing new drugs to market and significantly increased business revenues through the identification of new pathways across multiple indications.

Über die Innoplexus AG

Innoplexus AG is a leading global AI-champion with over 300 employees and 90+ patent applications in Artificial Intelligence, Machine Learning, and Blockchain technologies. Innoplexus applies its proprietary tech stack in all stages of the drug development value chain via smart Data as a Service (DaaS) and Continuous Analytics as a Service (CaaS) solutions. Generating real-time insights from 100s of Terabytes of structured and unstructured private and public data, Innoplexus helps organizations move towards continuous decision-making. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany with offices in Pune, India, and Hoboken, USA.

Firmenkontakt und Herausgeber der Meldung:

Innoplexus AG
Frankfurter Strasse 63
65760 Eschborn
Telefon: +49 (6196) 7774285
http://www.innoplexus.com

Ansprechpartner:
Silke Otte
Marketing und PR
Telefon: +49 (6196) 7774285
E-Mail: silke.otte@innoplexus.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel